| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/01/2005 | WO2005080432A2 Cdr-repaired antibodies |
| 09/01/2005 | WO2005080431A2 Monoclonal antibodies that specifically bind to folate receptor alpha |
| 09/01/2005 | WO2005080430A2 Anti-ube4a/ufd2b polyclonal antibody and its use thereof as diagnostic and prognostic marker of 11q23 region alterations |
| 09/01/2005 | WO2005080429A2 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| 09/01/2005 | WO2005080428A2 Anti-epcam immunoglobulins |
| 09/01/2005 | WO2005080423A1 Antifungal peptides |
| 09/01/2005 | WO2005079862A1 USE OF RESISTIN ANTISENSE OLIGONUCLEOTIDES AND/OR siRNA MOLECULES IN THE TREATMENT OF RHEUMATOID ARTHRITIS |
| 09/01/2005 | WO2005079848A2 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| 09/01/2005 | WO2005079844A2 Use for interleukin-33 (il33) and the il-33 receptor complex |
| 09/01/2005 | WO2005079830A1 Inhibitors of amyloid fibril formation and uses thereof |
| 09/01/2005 | WO2005079766A2 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| 09/01/2005 | WO2005079515A2 Conformation specific antibodies |
| 09/01/2005 | WO2005079508A2 Method and composition for angiogenesis inhibition |
| 09/01/2005 | WO2005079490A2 Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides |
| 09/01/2005 | WO2005079489A2 Method of treating cancer and identifying novel anti-ancer compounds |
| 09/01/2005 | WO2005079479A2 Super-humanized antibodies against respiratory syncytial virus |
| 09/01/2005 | WO2005079423A2 Chemically programmable immunity |
| 09/01/2005 | WO2005079398A2 Drug conjugates |
| 09/01/2005 | WO2005079267A2 Methods for protein production |
| 09/01/2005 | WO2005079243A2 Compositions and methods for identifying sperm for forensic applications |
| 09/01/2005 | WO2005058966A3 Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases |
| 09/01/2005 | WO2005054290A3 Peptide hormones zalpha48 and zsig97 |
| 09/01/2005 | WO2004073656A9 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 09/01/2005 | WO2004067718A3 Necrosis-deficient mutants of tuberculosis bacteria |
| 09/01/2005 | WO2004060911A3 Combination therapy with co-stimulatory factors |
| 09/01/2005 | WO2004056308A3 CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS |
| 09/01/2005 | WO2004044553A3 Lepidoptera voltage-gated calcium channels |
| 09/01/2005 | WO2004024076A8 Novel compositions and methods for the treatment of immune related diseases |
| 09/01/2005 | WO2004008099A3 METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 09/01/2005 | WO2003089651A3 Assay for quantitating secreted antibodies in lymphocytes supernatant |
| 09/01/2005 | WO2002083873A3 Enzymes |
| 09/01/2005 | US20050192429 Immunoglobulin mixture specific to endothelial growth factor for use as tools in treatment and prevention of cell prolifreative disorders; antitumor agents |
| 09/01/2005 | US20050192241 Administering to the joint having systemic onset juvenile idiopathic arthritis an active agent that will reduce the bioavailability of interleukin-1 beta (IL-1 beta) by modifying the transcription, translation or gene expression or by blocking the IL-1 beta recepter;antiinflammatory agent; antipyretics |
| 09/01/2005 | US20050191749 Novel plasmid vectors |
| 09/01/2005 | US20050191740 Using tissue specific gene transfer element as tool in somatic gene therapy |
| 09/01/2005 | US20050191735 Oxidoreductase |
| 09/01/2005 | US20050191726 Expression of heterologous multi-domain proteins in yeast |
| 09/01/2005 | US20050191725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/01/2005 | US20050191723 Improving gene expression in host cells vial use of vector comprising stabilizing anti-repressor (STAR) sequences; enhancer elements |
| 09/01/2005 | US20050191721 Tim-3 (t cell immunoglobulin and mucin domain containing molecule) polypeptide for use in enhancement of immune and transplantaion tolerance |
| 09/01/2005 | US20050191720 A vector for the surface expression of antibiotics composed of one or more genes that encode the synthetase and a gene encoding an amphiphilic peptide antibiotic having antibacterial, antifungal and anticancer activities; lactic acid-forming bacteria transformed with the vector |
| 09/01/2005 | US20050191712 immunoassay of acidic repeat protein/immunogens; solid phase synthesis; kits for diagnosis of syphilis |
| 09/01/2005 | US20050191711 Cerebral amyloid plaque precursors for use as diagnostic tool in detection of nervous system disorders |
| 09/01/2005 | US20050191702 Immunoglobulin comprising chemokine receptor binding domain and T cell surface polypeptide for use in prevention and treatment of nervous system, skin, diabetes, graft versus host, inflammatory joint and autoimmune diseases |
| 09/01/2005 | US20050191696 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products |
| 09/01/2005 | US20050191650 Used to reduce body temperature, suppress appetite, and therapy or prophylaxis of congestive heart failure and various stress-related disorders |
| 09/01/2005 | US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders |
| 09/01/2005 | US20050191631 Screening compounds for centromere-associated protein E (CENP-E) activity by determining plus end-directed microtubule motor activity, ATPase activity, or microtubule binding activity of a candidate compound, especially on Xenopus CENP-E |
| 09/01/2005 | US20050191617 Pramyxovirusl vectors encoding antibody and utilization thereof |
| 09/01/2005 | US20050191342 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 09/01/2005 | US20050191316 Neisseria genomic sequences and methods of their use |
| 09/01/2005 | US20050191314 vaccine comprosing a mixture of A beta oligomers capable of generating an immune response; prophylaxis and treatment of Alzheimer's disease |
| 09/01/2005 | US20050191313 Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation |
| 09/01/2005 | US20050191306 Cancerous disease modifying antibodies |
| 09/01/2005 | US20050191305 Cancerous disease modifying antibodies |
| 09/01/2005 | US20050191304 Employing Zvegf3 antagonists |
| 09/01/2005 | US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
| 09/01/2005 | US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 09/01/2005 | US20050191299 Identifying an inhibitor of CD70 by contacting a candidate CD70 inhibitor with a preparation of antigen presenting lamina propria (APCLP) cells; determining response of candidate inhbitor on gene expression of CD70 by said cells, and selecting an inhibitor; high throughput screening |
| 09/01/2005 | US20050191297 Sampling from biopsy of transplanted graft; administering a CD20 antagonist such as rituximab, humanized 2H7, or antibody conjugated to cytotoxic agent |
| 09/01/2005 | US20050191296 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof |
| 09/01/2005 | US20050191293 Isolated human monoclonal antibody, or an antigen-binding portion thereof; binds to human IP-10 (nterferon gamma inducible protein); cross-reacts with Rhesus monkey IP-10; inhibits calcium flux and cell migration; does not cross-react with mouse IP-10; autoimmune diseases; antiinflammatory agents |
| 09/01/2005 | US20050191292 of reversing cognitive decline by administering a humanized antibody that binds to A beta; particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease or Down's syndrome. |
| 09/01/2005 | US20050191290 Cell with immunoglobulin-free light chain (Ig-LC) receptor capable of activating signal transduction pathway upon binding to receptor; mast cell is activated and stimulated to degranulate; skin disorders, asthma, psoriasis, inflammatory bowel disease, rheumatoid arthritis, lupus, Sjogren*s syndrome |
| 09/01/2005 | US20050191283 Methods of treating NFAT-related disorders |
| 09/01/2005 | US20050191280 Immune regulation |
| 09/01/2005 | US20050191276 Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase |
| 09/01/2005 | US20050191239 Reacting a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, DOTA chelating agent and a protein to form the conjugate, reacting the conjugate with a quenching agent of hydroxylamine at an alkaline pH |
| 09/01/2005 | CA2558770A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions |
| 09/01/2005 | CA2558685A1 Nucleic acid construct containing fulllength genome of human hepatitis c virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferredthereinto and method of producing hepatitis c viral particle |
| 09/01/2005 | CA2557424A1 Methods for protein production |
| 09/01/2005 | CA2557333A1 Antifungal peptides |
| 09/01/2005 | CA2556913A1 Solid-fluid composition and uses thereof |
| 09/01/2005 | CA2556861A1 Protein ligands for nkg2d and ul16 receptors and uses thereof |
| 09/01/2005 | CA2556027A1 Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| 09/01/2005 | CA2555820A1 Cdr-repaired antibodies |
| 09/01/2005 | CA2555694A1 Anti-epcam immunoglobulins |
| 09/01/2005 | CA2555641A1 Drug conjugates |
| 09/01/2005 | CA2555421A1 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| 09/01/2005 | CA2555236A1 Methods of modulating cytokine activity; related reagents |
| 09/01/2005 | CA2555210A1 Chemically programmable immunity |
| 09/01/2005 | CA2554965A1 Antibodies specific for activated confirmation of lfa-1 |
| 09/01/2005 | CA2554537A1 Method and composition for angiogenesis inhibition |
| 09/01/2005 | CA2554263A1 Composition for treating pagthology associated with msrv/herv-w |
| 08/31/2005 | EP1568775A1 Cancer-associated gene |
| 08/31/2005 | EP1568767A2 Dna fragments of lav genes |
| 08/31/2005 | EP1568711A1 Composition containing immunoglobulins against rotavirus |
| 08/31/2005 | EP1568710A2 Antibody purification method |
| 08/31/2005 | EP1568708A2 Methods and medical uses of nucleic acids encoding a TRAF inhibitor |
| 08/31/2005 | EP1568378A1 Passive immunization against clostridium difficile disease |
| 08/31/2005 | EP1568376A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 08/31/2005 | EP1567868A2 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 08/31/2005 | EP1567863A2 Methods of therapy and diagnosis |
| 08/31/2005 | EP1567663A2 Molecular determinants of myeloma bone disease and uses thereof |
| 08/31/2005 | EP1567644A2 Tissue specific genes and gene clusters |
| 08/31/2005 | EP1567557A1 Monoclonal anti-na, k-atpase-beta-3 subunit antibody p-3e10 and use thereof as a therapeutic agent |
| 08/31/2005 | EP1567556A2 Recombinant immunotoxin and use in treating tumors |
| 08/31/2005 | EP1567555A2 Humanized antibodies against monocyte chemotactic proteins |
| 08/31/2005 | EP1567544A2 Use of hmgb polypeptides for increasing immune responses |
| 08/31/2005 | EP1567541A2 Rationally designed antibodies |